Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?

per AL-Mansouri, Loma, Arasaratnam, Malmaruha, Gurney, Howard
Publicat a Eur J Hosp Pharm (2021)

Inhibitors of mTOR

per Klümpen, Heinz-Josef, Beijnen, Jos H., Gurney, Howard, Schellens, Jan H.M.
Publicat 2010

Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival

per Patel, Manish I., Beattie, Kieran, Bang, Albert, Gurney, Howard, Smith, David P.
Publicat a Cancer Med (2017)

Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?

per Sabanathan, Dhanusha, Park, John J., Marquez, Manuel, Francisco, Louise, Byrne, Natalie, Gurney, Howard
Publicat a Oncologist (2017)

The Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and the Benefits and Potential Anti-oncogenic Mechanisms of Progressive Resistance Training

per Lam, Teresa, Birzniece, Vita, McLean, Mark, Gurney, Howard, Hayden, Amy, Cheema, Birinder S.
Publicat a Sports Med Open (2020)

Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study

per Rapport, Frances, Hogden, Anne, Gurney, Howard, Gillatt, David, Bierbaum, Mia, Shih, Patti, Churruca, Kate
Publicat a BMJ Open (2017)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment

per Attard, Gerhardt, Borre, Michael, Gurney, Howard, Loriot, Yohann, Andresen-Daniil, Corina, Kalleda, Ranjith, Pham, Trinh, Taplin, Mary-Ellen
Publicat a J Clin Oncol (2018)

Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2

per Zhou, Fanfan, Zheng, Jian, Zhu, Ling, Jodal, Andreas, Cui, Pei H., Wong, Mark, Gurney, Howard, Church, W. Bret, Murray, Michael
Publicat 2013

Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews

per van Leeuwen, Marina T, Luu, Steven, Gurney, Howard, Brown, Martin R, Webber, Kate, Pearson, Sallie-Anne, Hunt, Lee, Vajdic, Claire M
Publicat a BMJ Open (2018)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

per Hopkins, Ashley M, Rowland, Andrew, Kichenadasse, Ganessan, Wiese, Michael D, Gurney, Howard, McKinnon, Ross A, Karapetis, Chris S, Sorich, Michael J
Publicat a Br J Cancer (2017)

Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia

per Carus, Andreas, Gurney, Howard, Gebski, Val, Harnett, Paul, Hui, Rina, Kefford, Richard, Wilcken, Nicholas, Ladekarl, Morten, von der Maase, Hans, Donskov, Frede
Publicat 2013

Nuances to precision dosing strategies of targeted cancer medicines

per Hopkins, Ashley M., Menz, Bradley D., Wiese, Michael D., Kichenadasse, Ganessan, Gurney, Howard, McKinnon, Ross A., Rowland, Andrew, Sorich, Michael J.
Publicat a Pharmacol Res Perspect (2020)

A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy

per Lam, Teresa, McLean, Mark, Hayden, Amy, Poljak, Anne, Cheema, Birinder, Gurney, Howard, Stone, Glenn, Bahl, Neha, Reddy, Navneeta, Shahidipour, Haleh, Birzniece, Vita
Publicat a Endocr Connect (2019)

Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews

per Van Leeuwen, Marina T, Luu, Steven, Gurney, Howard, Brown, Martin R, Pearson, Sallie-Anne, Webber, Kate, Hunt, Lee, Hong, Soojung, Delaney, Geoffrey P, Vajdic, Claire M
Publicat a JNCI Cancer Spectr (2020)

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer

per Lin, Hui-Ming, Mahon, Kate L, Spielman, Calan, Gurney, Howard, Mallesara, Girish, Stockler, Martin R, Bastick, Patricia, Briscoe, Karen, Marx, Gavin, Swarbrick, Alexander, Horvath, Lisa G
Publicat a Br J Cancer (2017)

Androgen deprivation in prostate cancer: benefits of home-based resistance training

per Lam, Teresa, Cheema, Birinder, Hayden, Amy, Lord, Stephen R., Gurney, Howard, Gounden, Shivanjini, Reddy, Navneeta, Shahidipour, Haleh, Read, Scott, Stone, Glenn, McLean, Mark, Birzniece, Vita
Publicat a Sports Med Open (2020)

High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation

per Nath, Christa E., Trotman, Judith, Tiley, Campbell, Presgrave, Peter, Joshua, Douglas, Kerridge, Ian, Kwan, Yiu Lam, Gurney, Howard, McLachlan, Andrew J., Earl, John W., Nivison‐Smith, Ian, Zeng, Lihua, Shaw, Peter J.
Publicat a Br J Clin Pharmacol (2016)

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy

per Nath, Christa E, Shaw, Peter J, Trotman, Judith, Zeng, Lihua, Duffull, Stephen B, Hegarty, Gareth, McLachlan, Andrew J, Gurney, Howard, Kerridge, Ian, Kwan, Yiu Lam, Presgrave, Peter, Tiley, Campbell, Joshua, Douglas, Earl, John
Publicat 2010

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio

per Lee, Clara Inkyung, Low, Siew Kee, Maldonado, Ricardo, Fox, Peter, Balakrishnar, Bavanthi, Coulter, Sally, de Bruijn, Peter, Koolen, Stijn L.W., Gao, Bo, Lynch, Jodi, Zdenkowski, Nicholas, Hui, Rina, Liddle, Christopher, Mathijssen, Ron H.J., Wilcken, Nicholas, Wong, Mark, Gurney, Howard
Publicat a Breast (2020)

High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol...

per Nair-Shalliker, Visalini, Smith, David P, Gebski, Val, Patel, Manish I, Frydenberg, Mark, Yaxley, John W, Gardiner, Robert, Espinoza, David, Kimlin, Michael G, Fenech, Michael, Gillatt, David, Woo, Henry, Armstrong, Bruce K, Rasiah, Krishan, Awad, Nader, Symons, James, Gurney, Howard
Publicat a BMJ Open (2021)